News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases
Friday, December 16, 2022Sosei Group Corporation announces it has entered a drug discovery collaboration with Eli Lilly and Company Lilly a global biopharmaceutical company to discover develop and commercialize small molecules that modulate novel G proteincoupled receptor GP...
Poolbeg Pharma PLC Announces Metabolic Diseases Oral Delivery Licence Signed
Thursday, December 15, 2022Poolbeg Pharma a leading infectious disease focused biopharmaceutical company announces that it has acquired an exclusive licence from InsuCaps Limited InsuCaps a sister company of AnaBio Technologies AnaBio to use InsuCaps patented microencapsulatio...
PrecisionLife Enters into a Multi Target R&D Collaboration Agreement with Ono Pharmaceutical
Thursday, December 15, 2022PrecisionLife Limited a global techbio company generating the deepest insights into disease biology to create novel precision medicines in chronic diseases today announced that it has entered into a multitarget discovery and validation partnership wi...
Sharps Technology and Nephron Pharmaceuticals Sign Distribution Agreement for its Innovative Syringe Products
Wednesday, December 14, 2022Sharps Technology Inc an innovative medical device and drug delivery Company offering patented bestinclass syringe products is pleased to announce the signing of a distribution agreement with partner Nephron Pharmaceuticals This is a strategic first...
Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome
Wednesday, December 14, 2022Quoin Pharmaceuticals Ltd a specialty pharmaceutical company focused on rare and orphan diseases announces that the first patient has been dosed in its ongoing clinical trial evaluating the safety and efficacy of QRX as a treatment for Netherton Synd...
CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics
Tuesday, December 13, 2022CSL Limited announced that its subsidiary CSL Seqirus finalized its global collaboration and license agreement with Arcturus Therapeutics Holdings Inc The agreement grants access to Arcturus Therapeutics late stage selfamplifying mRNA samRNA vaccine...
SynAct Pharma to make strategic acquisition of Swiss biotech company TXP Pharma
Tuesday, December 13, 2022SynAct Pharma AB announced that the Company has entered into a conditional agreement on acquisition of TXP Pharma AG TXP a privately owned Swissincorporated biotech company researching and developing pharmaceutical drugs for the treatment of autoimmu...
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
Friday, December 09, 2022Pfizer Inc and BioNTech SE announced the US Food and Drug Administration FDA granted Emergency Use Authorization EUA of their Omicron BABAadapted bivalent COVID vaccine as the third g dose in the threedose primary series for children months through...
Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration
Friday, December 09, 2022Addex Therapeutics a clinicalstage pharmaceutical company pioneering allosteric modulationbased drug discovery and development today announced that the research term of its collaboration agreement with Indivior PLC LON INDV for the discovery of novel...
Inhibikase Therapeutics Provides Update to FDA Clinical Hold of IkT-148009 Programs
Thursday, December 08, 2022Inhibikase Therapeutics Inc a clinicalstage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinsons disease PD Parkinsonsrelated disorders and other diseases of the Abelson Tyrosine Kinases announced...
